Clinical Research Papers:

Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC)

Lianyuan Tao, Lingfu Zhang, Ying Peng, Ming Tao, Gang Li, Dianrong Xiu, Chunhui Yuan _, Chaolai Ma and Bin Jiang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:74314-74324. https://doi.org/10.18632/oncotarget.11031

Metrics: PDF 1591 views  |   HTML 2270 views  |   ?  


Lianyuan Tao1, Lingfu Zhang1, Ying Peng1, Ming Tao1, Gang Li1, Dianrong Xiu1, Chunhui Yuan1, Chaolai Ma1 and Bin Jiang1

1 Department of General Surgery, Peking University Third Hospital, Beijing, China

Correspondence to:

Dianrong Xiu, email:

Keywords: pancreatic ductal adenocarcinoma; lymph node metastasis; prognosis; neutrophil-to-lymphocyte ratio

Received: May 09, 2016 Accepted: July 19, 2016 Published: August 02, 2016


As a poor prognosis indicator in patients with pancreatic ductal adenocarcinoma (PDCA), lymph node (LN) metastasis is of great importance in treatment. Present study was performed to evaluate the predictive value of preoperative neutrophil-to-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and possible clinical parameters on the LN metastasis in PDCA patients. A total of 159 operable patients with PDCA were enrolled in our study. The clinical utility of NLR and other clinical parameters was evaluated by receiver operating characteristic (ROC) curves. Overall survival analysis indicated that LN metastasis is an independent prognostic factor. The logistic analysis was used to determine the independent parameters associated with LN metastasis. Ideal cutoff values for predicting LN metastasis are 2.12 for NLR and 130.96 for PLR according to the ROC curve. Multivariate analyses indicate that NLR (HR 2.588; 95% CI 1.246-5.376; P = 0.011), CA125 (HR 6.348; 95% CI 2.056-19.594; P = 0.001) and CA19-9 (HR 2.738; 95% CI 1.151-6.515; P = 0.023) are associated significantly with LN metastasis independently. Preoperative NLR, CA125 and CA19-9 are useful biomarkers for the prediction of LN metastasis in PDCA patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11031